{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:22:55Z","timestamp":1777681375981,"version":"3.51.4"},"reference-count":65,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Public health advocates and healthcare professionals (HCPs) have been challenged with vaccine hesitancy and addressing misinformation. In order for HCPs and pharmacists, in particular, to serve as effective stewards of COVID-19 vaccine science in the interest of the public good, it is imperative for HCPs to appreciate the various factors contributing to vaccine hesitancy and vaccine distrust. A PubMed search was performed and relevant articles on COVID-19 vaccine in populations of interest were included. Information from health agencies, such as the Centers for Disease Control and Prevention (CDC) as well as established professional health societies was incorporated for guidance. This review focuses on COVID-19 vaccine concerns in the populations of children, pregnancy and lactation, immunocompromised, and religious and ethnic disparities. We also discuss post emergency use authorization experience with respect to vaccine safety including annotations on Guillain-Barr\u00e9 Syndrome, myocarditis and pericarditis, and thrombosis with thrombocytopenia syndrome.<\/jats:p>","DOI":"10.1177\/00185787211066463","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T07:16:49Z","timestamp":1642576609000},"page":"575-587","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Narrative Review: Addressing Covid-19 Vaccine Concerns in Special and Vulnerable Populations"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7923-3039","authenticated-orcid":false,"given":"Kent A.","family":"Owusu","sequence":"first","affiliation":[{"name":"Yale New Haven Health, New Haven, CT, USA"},{"name":"Yale New Haven Hospital, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad K.","family":"Effendi","sequence":"additional","affiliation":[{"name":"Ernest Mario School of Pharmacy, Piscataway, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8047-5978","authenticated-orcid":false,"given":"Melissa L.","family":"Thompson Bastin","sequence":"additional","affiliation":[{"name":"University of Kentucky HealthCare, Lexington, KY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samad","family":"Tirmizi","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishaq","family":"Lat","sequence":"additional","affiliation":[{"name":"Shirley Ryan AbilityLab, Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"Ammar","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"bibr1-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7361.430"},{"key":"bibr2-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440511"},{"key":"bibr3-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116298"},{"key":"bibr4-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.03.023"},{"key":"bibr5-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab353"},{"key":"bibr6-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4385"},{"key":"bibr7-00185787211066463","doi-asserted-by":"publisher","DOI":"10.7326\/M20-6306"},{"key":"bibr8-00185787211066463","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.05015"},{"key":"bibr9-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00099-1"},{"issue":"16","key":"bibr10-00185787211066463","volume":"385","author":"Shimabukuro TT","year":"2021","journal-title":"N Engl J Med"},{"key":"bibr11-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.4573"},{"key":"bibr12-00185787211066463","unstructured":"American Academy of Pediatrics. Children and COVID-19: state-level data report. 2020. Accessed November 11, 2021. https:\/\/www.aap.org\/en\/pages\/2019-novel-coronavirus-covid-19-infections\/children-and-covid-19-state-level-data-report"},{"key":"bibr13-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.08.037"},{"key":"bibr14-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy142"},{"key":"bibr15-00185787211066463","unstructured":"Centers for Disease Control and Prevention. COVID-19 vaccination program interim playbook for jurisdiction operations. Version 1.0. 2020. Accessed August 18, 2021. https:\/\/www.cdc.gov\/vaccines\/covid-19\/downloads\/COVID-19-vaccination-program-playbook-annex.pdf"},{"key":"bibr16-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.2091"},{"key":"bibr17-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-020-00739-6"},{"key":"bibr18-00185787211066463","first-page":"1","volume":"24","author":"Cooper DM","year":"2021","journal-title":"Pediatr Res"},{"key":"bibr19-00185787211066463","unstructured":"U.S. Food and Drug Administration. Would your child benefit from a clinical trial? 2017. Accessed May 15, 2021. https:\/\/www.fda.gov\/consumers\/consumer-updates\/would-your-child-benefit-clinical-trial"},{"key":"bibr20-00185787211066463","unstructured":"U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine EUA letter of authorization. 2021. Accessed May 15, 2021. https:\/\/www.fda.gov\/media\/144412\/download"},{"key":"bibr21-00185787211066463","unstructured":"Pfizer-BioNTech COVID-19 Vaccine [Full Emergency Use Authorization (EUA) Prescribing Information]\n                      . Pfizer Inc; 2021."},{"key":"bibr22-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab344"},{"key":"bibr23-00185787211066463","unstructured":"Society for Maternal Fetal Medicine. Provider considerations for engaging in COVID-19 vaccine counseling with pregnant and lactating patients. 2021. Accessed August 18, 2021. https:\/\/www.smfm.org\/covidclinical"},{"key":"bibr24-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.11035"},{"key":"bibr25-00185787211066463","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA takes additional actions on the use of booster dose for COVID-19 vaccines [Press release]. October 20, 2021. Accessed November 11, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines"},{"key":"bibr26-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"bibr27-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4"},{"key":"bibr28-00185787211066463","unstructured":"Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. U.S. Department of Health and Human Services. Accessed November 11, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html"},{"key":"bibr29-00185787211066463","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7044e2"},{"key":"bibr30-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255"},{"key":"bibr31-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001145"},{"key":"bibr32-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1177688"},{"key":"bibr33-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100051"},{"key":"bibr34-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13495"},{"key":"bibr35-00185787211066463","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.20056"},{"key":"bibr36-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit684"},{"key":"bibr37-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"bibr38-00185787211066463","unstructured":"National Multiple Sclerosis Society. Timing MS medications with COVID-19 vaccines. Accessed May 24, 2021. https:\/\/www.nationalmssociety.org\/coronavirus-covid-19-information\/multiple-sclerosis-and-coronavirus\/covid-19-vaccine-guidance\/Timing-MS-Medications-with-COVID-19-mRNA-Vaccines"},{"key":"bibr39-00185787211066463","doi-asserted-by":"publisher","DOI":"10.5152\/tpa.2014.2206"},{"key":"bibr40-00185787211066463","unstructured":"American Society of Hematology. General principles of COVID-19 vaccines for immunocompromised patients. Accessed May 21, 2021. https:\/\/www.hematology.org\/covid-19\/ash-astct-covid-19-and-vaccines"},{"key":"bibr41-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2103104"},{"key":"bibr42-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMpv2035827"},{"key":"bibr43-00185787211066463","unstructured":"Centers for Disease Control and Prevention. Vaccine equity for racial and ethnic minority groups. Centers for Disease Control and Prevention. Published July 19, 2021. Accessed August 11, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/community\/health-equity\/vaccine-equity.html"},{"key":"bibr44-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26443"},{"key":"bibr45-00185787211066463","unstructured":"Centers for Disease Control and Prevention. United States COVID-19 cases and deaths by state. Accessed May 16, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker\/#cases_casesper100klast7days"},{"key":"bibr46-00185787211066463","unstructured":"Centers for Disease Control and Prevention. COVID-19 racial and ethnic health disparities. Accessed May 16, 2021. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/community\/health-equity\/racial-ethnic-disparities\/what-we-do.html"},{"key":"bibr47-00185787211066463","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. Published March 28, 2020. Accessed May 25, 2021. https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"bibr48-00185787211066463","unstructured":"U.S. Census Bureau. 2020). Census Bureau releases 2020 demographic analysis estimates. 2020. Accessed June 2, 2021. https:\/\/www.census.gov\/newsroom\/press-releases\/2020\/2020-demographic-analysis-estimates.html"},{"key":"bibr49-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.1445"},{"issue":"2","key":"bibr50-00185787211066463","first-page":"56","volume":"14","author":"Kennedy BR","year":"2007","journal-title":"J Cult Divers"},{"key":"bibr51-00185787211066463","author":"Abdul-Mutakabbir JC","journal-title":"European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"bibr52-00185787211066463","unstructured":"Fadel H. Use of heparin. Brochure: Islamic Medical Association of North America. Accessed May 21, 2021. https:\/\/imana.org\/resources\/imana-brochure-use-of-heparin\/"},{"key":"bibr53-00185787211066463","unstructured":"PRRI. Faith-based approaches can positively impact COVID-19 vaccination efforts: religious identities and the race against the virus. PRRI-IFYC. Published April 22, 2021. Accessed May 21, 2021. www.prri.org\/research\/prri-ifyc-covid-vaccine-religion-report\/"},{"key":"bibr54-00185787211066463","unstructured":"Institute of Medicine (US) Conference Committee on Fetal Research and Applications. Fetal Research and Applications: A Conference Summary. Setting the Stage: Fetal Research, Fetal Tissue Research, and Historical Timeline of Regulation and Legislation. National Academies Press; 1994. Accessed May 21, 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK231997\/"},{"key":"bibr55-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1126\/science.368.6496.1170"},{"key":"bibr56-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400472111"},{"key":"bibr57-00185787211066463","volume-title":"Moderna COVID-19 Vaccine [Full Emergency Use Authorization (EUA) Prescribing Information]","author":"U.S. Food and Drug Administration","year":"2021"},{"key":"bibr58-00185787211066463","volume-title":"Johnson & Johnson (J&J\/Janssen) COVID-19 Vaccine [Full Emergency Use Authorization (EUA) Prescribing Information]","author":"J&amp;J\/Janssen Biotech Inc","year":"2021"},{"key":"bibr59-00185787211066463","volume-title":"AstraZeneca COVID-19 vaccine (COVID-19 vaccine [ChAdOx1-S Recombinant]) [Product Monograph]","author":"AstraZeneca","year":"2021"},{"key":"bibr60-00185787211066463","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7017e4"},{"key":"bibr61-00185787211066463","unstructured":"Centers for Disease Control and Prevention. Cases of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Receipt of the Johnson & Johnson COVID-19 Vaccine. Health Alert Network (HAN). US Department of Health and Human Services, CDC; 2021.Accessed November 18, 2021. https:\/\/emergency.cdc.gov\/han\/2021\/han00442.asp\/"},{"key":"bibr62-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2821"},{"key":"bibr63-00185787211066463","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-052478"},{"key":"bibr64-00185787211066463","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7027e2"},{"key":"bibr65-00185787211066463","unstructured":"United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) \/ Food and Drug Administration (FDA). Vaccine Adverse Event Reporting System (VAERS) 1990 - 07\/30\/2021, CDC WONDER On-line Database. Accessed August 12, 2021. http:\/\/wonder.cdc.gov\/vaers.html"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211066463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787211066463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787211066463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:39:45Z","timestamp":1777451985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787211066463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1177\/00185787211066463"],"URL":"https:\/\/doi.org\/10.1177\/00185787211066463","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]}}}